Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 8Lymphoma, Non-Hodgkin 4Lymphoma 4Breast Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Lung Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia 2Hodgkin Disease 2Hematologic Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Toxemia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Sezary Syndrome 1

Interventions

Gemcitabine 32Cisplatin 31durvalumab 15pembrolizumab 14Fluorouracil 13Oxaliplatin 12Leucovorin 12Capecitabine 10Bevacizumab 8lenvatinib 7Nivolumab 7zanidatamab 4Trastuzumab 4S 1 (combination) 4Paclitaxel 4Liquid Biopsy 4Irinotecan 4Carboplatin 4Albumin-Bound Paclitaxel 4tremelimumab 3tislelizumab 3irinotecan sucrosofate 3Injections 3Folfox protocol 3130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2niraparib 2ivosidenib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Positron-Emission Tomography × 1 year × Clear all
NCT00924027 2025-09-05

A Study of Patients Receiving High-Dose Rate Brachytherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
43 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Biliary Tract Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡